The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis
Abstract
Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 and subsequent elucidation of the varied CFTR protein abnormalities that result, a new era of cystic fibrosis management has emerged-one in which scientific principles translated from the bench to the bedside have enabled us to potentially treat the basic defect in the majority of children and adults with cystic fibrosis, with a resultant burgeoning adult cystic fibrosis population. However, the long-term effects of these therapies on the multiple manifestations of cystic fibrosis are still under investigation. Understanding the effects of modulators in populations excluded from clinical trials is also crucial. Furthermore, establishing appropriate disease measures to assess efficacy in the youngest potential trial participants and in those whose post-modulator lung function is in the typical range for people without chronic lung disease is essential for continued drug development. Finally, recognising that a health outcome gap has been created for some people and widened for others who are not eligible for, cannot tolerate, or do not have access to modulators is important.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Excessive synaptic strengthening, prolonged translational disinhibition, or poorly calibrated excitability modulation could promote maladaptive plasticity, excitotoxic stress, epileptiform activity, or aberrant stabilization of pathological circuit states.”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [434]
Citations
Cites
Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198
Self-citationA CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32597-8 · Cited by 1,414
Self-citationRescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,228
CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE: A CLINICAL AND PATHOLOGIC STUDY
ANDERSEN, D. H. (1938) · American Journal of Diseases of Children · doi:10.1001/archpedi.1938.01980140114013 · Cited by 1,146
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
Research works printed but not linked: 2
- Zemanick, 2021, A phase 3 open-label study of ELX/TEZ/IVA in children 6 through 11 years of age with CF and at least one F508del allele, Am J Respir Crit Care Med, 203, 1522, 10.1164/rccm.202102-0509OC · DOI · Paper page
- Sawicki, 2015, Rate of uptake of ivacaftor use after US Food and Drug Administration approval among patients enrolled in the US Cystic Fibrosis Foundation patient registry, Ann Am Thorac Soc, 12, 1146
Cited by
Neutrophil diversity and function in health and disease
Zhang, F., Xia, Y., Su, J., Quan, F., Zhou, H., Li, Q., Feng, Q., Lin, C., Wang, D., & Jiang, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02049-y · Cited by 246
Mall, M. A., Burgel, P.-R., Castellani, C., Davies, J. C., Salathe, M., & Taylor-Cousar, J. L. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00538-6 · Cited by 206
“Consequently, the full effects of early-life therapy are not yet clear and we have much still to learn from post-license surveillance studies and registry data 320 .”
InfluentialSelf-citationThe future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches
Graeber, S. Y., & Mall, M. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01608-2 · Cited by 167
Pseudomonas aeruginosa in chronic lung disease: untangling the dysregulated host immune response
Nickerson, R., Thornton, C. S., Johnston, B., Lee, A. H., & Cheng, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1405376 · Cited by 79
“CFTR modulators fall into 2 functional categories: potentiators, which enhance the channel opening probability of CFTR, and correctors, which improve CFTR folding and traf fi cking (3, 336).”
BackgroundTargeting neutrophil serine proteases in bronchiectasis
Chalmers, J. D., Mall, M. A., Chotirmall, S. H., O’Donnell, A. E., Flume, P. A., Hasegawa, N., Ringshausen, F. C., Watz, H., Xu, J., Shteinberg, M., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.01050-2024 · Cited by 81
Self-citation
Metadata
- Authors
- Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G.
- Affiliations
- The University of Queensland (AU)
- Technion – Israel Institute of Technology (IL)
- Queen's University Belfast (GB)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 402
- Issue
- 10408
- Pages
- 1171-1184
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4386565807
- Cited by
- 173
- References
- 128
- Citations by year
- 2026: 55 · 2025: 68 · 2024: 39 · 2023: 10
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- CFTR modulator therapy, cystic fibrosis, CFTR, adults with cystic fibrosis, long-term drug effects, inclusion and exclusion criteria, drug development, access to treatment
- MeSH terms
- Adult, Aminophenols, Child, Cystic Fibrosis, Humans, Mutation, Genetic Therapy, Quinolones, Cystic Fibrosis Transmembrane Conductance Regulator
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. https://app.cochat.ai/papers/10.1016/s0140-6736(23)01609-4
- The paper
- Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G. (2023). CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. The Lancet. https://doi.org/10.1016/s0140-6736(23)01609-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.